Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck 2019 Restructuring Program (legacy) — Recorded in R&D ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, FY2023
1
Period ended Dec 31, 2023
Change on a year earlier
-96.7%
30 in FY2022
History
3 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2019 Restructuring Program (legacy) — Recorded in R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1 | -96.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 30 | +7.1% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 28 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck 2019 Restructuring Program (legacy) — Recorded in R&D ($M) ($M), annual FY2021–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2019_line_rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.